Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol for Prevention of Cardiotoxicity in Breast Cancer
NCT02993198Phase 2Active, not recruiting
- Sponsor
- Northwestern University
- Start
- Apr 2015
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carvedilol in Cardiotoxicity (4 arms), sponsored by Northwestern University. Primary endpoint: Change in Global Longitudinal Strain at 1 year. Started Apr 2015; status: active, not recruiting.
02
Drugs
carvedilol
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT02993198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993198.